Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Additional HYPER-H21-4 Study Findings Offer Better Understanding of the Anti-Hypertensive Effects of DehydraTECH-CBD
Dosing for Lexaria’s ambitious and most comprehensive clinical study, HYPER-H21-4, was successfully completed in July 2022, with newly analyzed results now emerging Its latest findings bring the company closer to its upcoming FDA Phase 1b study while also explaining the patented DehydraTECH-(TM)-processed CBD interaction with the sympatho-chromaffin system via catestatin modulation Lexaria’s management is optimistic that DehyraTECH-CBD and its effectiveness in modulating catestatin levels could become a significant value enhancer should it eventually enter the marketplace as an approved hypertension treatment Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, kicked off its human clinical study, HYPER-H21-1 in…
